Samsung Life Insurance (A032830) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
24 Jun, 2026Executive summary
Q3 net profit reached ₩674 billion, up 41.6% year-over-year, with YTD profit surpassing ₩2 trillion and CSM balance increasing by ₩0.7 trillion to ₩13 trillion, driven by strong health insurance and asset diversification.
Consolidated net income for 2024 Q3 was 2,165.9 billion KRW, with basic EPS of 11,372 KRW and total consolidated assets at 312.7 trillion KRW.
Profitability improved due to focus on high-quality health insurance and asset diversification.
Financial highlights
YTD consolidated net profit reached ₩2.042 trillion, up ₩592.4 billion year-over-year, with insurance service profit at ₩1.187 trillion and investment profit at ₩1.53 trillion.
3Q24 investment profit grew 73% year-over-year, driven by non-interest income and asset diversification.
Health products accounted for 62% of new business CSM in Q3, with YTD new business CSM at ₩2.5 trillion.
Shareholders' equity decreased by W9.1tn to W35.3tn due to regulatory changes and lower interest rates.
Total comprehensive income was a loss of 8,331.5 billion KRW, mainly due to negative other comprehensive income from financial asset revaluations.
Outlook and guidance
Targeting a mid-to-long-term shareholder return ratio of 50%, with dividend policy under review and FY24 new business CSM guidance set at W3.2tn.
Double-digit annual profit growth remains a goal, with value-up program and mid-to-long-term growth strategies in development.
Focus on digital transformation, risk management, and expansion in health and senior insurance markets.
Latest events from Samsung Life Insurance
- Net profit up 40.5% to KRW 1.37T in H1 2024; health CSM leads; 50% payout ratio targeted.A032830
Q2 20248 Jul 2026 - Q1 2025 net profit reached KRW 677.5B, assets KRW 318.9T, solvency margin 218.8%.A032830
Q1 20258 Jul 2026 - H1 2025 net profit up 1.9% to KRW 1.394T, KICS at 187%, assets KRW 319.1T, ESG AA.A032830
Q2 202524 Jun 2026 - Net profit up 3.7% YoY, with strong capital, health CSM growth, and higher equity.A032830
Q3 202524 Jun 2026 - Q1 net income up 89.5%–90% YoY, CSM and health product sales surged, K-ICS ratio at 210%.A032830
Q1 202621 May 2026 - FY2025 net profit rose 9.3% to KRW 2.3T, with record CSM and DPS up 18%; strong 2026 growth targeted.A032830
Q4 202512 Apr 2026 - Record profit, robust capital, and higher dividends driven by health segment growth.A032830
Q4 20248 Jan 2026